A number of collaborations are supporting the advancement of our pipeline
Summit seeks to maximise the value of its pipeline, which includes entering into collaborations with academic and government institutions and biotech and pharmaceutical companies.
For more information, or to inquire about in- or out-licensing opportunities, please contact firstname.lastname@example.org.
In 2017, we were awarded a contract worth up to $72.5 million from the US government agency, the Biomedical Advanced Research and Development Authority (‘BARDA’), to support the clinical and regulatory development of ridinilazole for the treatment of C. difficile infection.
In December 2017, we signed a regional licensing deal that granted Eurofarma Laboratórios exclusive rights to ridinilazole in South and Central America and certain Caribbean islands in exchange for development, regulatory and sales milestones, as well as product supply transfer payments.
The Wellcome Trust supported the development of ridinilazole from preclinical development through the completion of a Phase 2 clinical trial, with total contributions around $10 million from a Seeding Drug Discovery Award (2009) and Translational Research Award (2012).
In 2014, Roche entered into a multi-year research collaboration for undisclosed targets using our Discuva Platform. Roche has elected to continue work on these programmes and is solely responsible for the further development and commercialisation of these compounds. Under the terms of the collaboration agreement, Summit is eligible to receive milestone and royalty payments from Roche upon the achievement of specified development, commercialisation and sales milestones for any of the compounds that result from the collaboration.